Authors


Loren Winters, NP

Latest:

Implementing a Multidisciplinary Lifestyle Medicine Clinic for Cancer Survivorship

The lifestyle medicine needs of cancer survivors seeking lifestyle consultation are growing, and awareness of the benefits of lifestyle medicine for this population can enhance the quality of life for patients who are survivors of cancer.



Maham Maqsood, MBBS

Latest:

Navigating a Paradigm Shift Venetoclax Treatment Redefines Landscape of Acute Myeloid Leukemia

Investigators focused on the latest advances in the treatment of patients with AML, while prioritizing the use of venetoclax as it has been shown to significantly impact the course of the disease.


Daner Li, MS

Latest:

Circulating Tumor DNA as a Predictive Biomarker for Clinical Outcomes With Margetuximab and Pembrolizumab in Pretreated HER2-Positive Gastric/ Gastroesophageal Adenocarcinoma

Daniel V. T. Catenacci, MD, and colleagues present findings from a study of circulating tumor DNA as a predictive biomarker for gastric and gastroesophageal cancer.


Matthew Fowler, Associate Editor

Latest:

HER2+ Breast Cancer Clinical Pearls

Advice for community physicians treating HER2+ breast cancer.




Minqian Shen, MD, PhD

Latest:

Genomic Predictors Associated With Exceptional Response to Systemic Therapy in Advanced Pancreatic Cancer

Suneel K. Kamath, MD, et al investigated exceptional responders and the correlation of nonsynonymous mutations for patients with advanced pancreatic cancer.



Ryan Scott

Latest:

Novel Allogenic CAR T Therapy Shows Responses in R/R Multiple Myeloma

P-BCMA-ALLO1 yielded lymphodepletion responses even among those with prior exposure to other CAR T-cell therapies or bispecific agents.



Mira Gabrielle Basuino, BS

Latest:

Erdheim-Chester Disease: A Case Report of BRAF V600E–Negative, MAP2K1-Positive ECD Diagnosed by Blood Next-Generation Sequencing Assay and a Brief Literature Review

Investigators report a case of a man, aged 55 years, with an extensive and prolonged course of an unexplained multi-systemic disease, and also review common clinical manifestations, mutations, diagnoses, and targeted therapies for Erdheim-Chester disease.


Jacqueline Feinberg, MD

Latest:

Multidisciplinary Efforts are 'Essential' to Manage Gynecologic Cancer Symptoms

A recovery tracker and other digital tools may be useful in helping to manage patient symptoms following debulking surgery for gynecologic cancer, according to an expert from Memorial Sloan Kettering Cancer Center.





Louis Voigt, MD

Latest:

Decisional Capacity Determination in Patients With Cancer

Experts discuss the process of assessing decision-making capacity in patients with cancer.




Fay J. Hlubocky, PhD, MA

Latest:

Decisional Capacity Determination in Patients With Cancer

Experts discuss the process of assessing decision-making capacity in patients with cancer.



Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA

Latest:

Clinical Perspectives: Utilizing CAR-T Therapy in R/R MM

Panelists discuss how emerging data on chimeric antigen receptor T-cell therapies ciltacabtagene autoleucel and idecabtagene vicleucel for earlier treatment lines in relapsed/refractory multiple myeloma influence institutional decision-making factors for their implementation.


Eirwen Miller, MD

Latest:

Synchronous Well-Differentiated Papillary Mesothelioma and Endometrioid Adenocarcinoma Arising From Endometriosis

Learn more about a 56-year-old woman diagnosed with well-differentiated papillary mesothelioma, and how she was diagnosed and properly treated.


Andrew T. Kuykendall, MD

Latest:

Pelabresib in MPNs: Immune Profiles of Responders vs. Non-responders

Panelists discuss the immune profiles of responders vs non-responders to pelabresib in myeloproliferative neoplasms (MPNs).


Larry Fitzgerald

Latest:

The Post–CAR T Journey: Long-Term Monitoring, Multidisciplinary Care, and Continuous Patient Support

Panelists discuss how health care centers provide comprehensive long-term monitoring and support services for both patients receiving CAR T and their caregivers in the posttreatment period, including regular medical assessments and ongoing educational resources.


Jason M. Hafron, MD, CMO

Latest:

Optimization of Genetic Testing for mCRPC

Jason M. Hafron, MD, CMO, and Oliver Sartor, MD, share their approach for the optimal management of mCRPC through genetic testing.



Christine Chung, DO

Latest:

Oncology Peer Review On-The-Go: Characterization of Blood-Based Molecular Profiling in Pancreatic Adenocarcinoma

Christine Chung, DO, spoke with CancerNetwork® about the latest research from the journal ONCOLOGY® about implications of blood-based molecular markers in pancreatic adenocarcinoma.


Justin I. Odegaard, MD, PhD

Latest:

Circulating Tumor DNA as a Predictive Biomarker for Clinical Outcomes With Margetuximab and Pembrolizumab in Pretreated HER2-Positive Gastric/ Gastroesophageal Adenocarcinoma

Daniel V. T. Catenacci, MD, and colleagues present findings from a study of circulating tumor DNA as a predictive biomarker for gastric and gastroesophageal cancer.